Phase 1 N=9 TMS and Exercise for Post-stroke Pain
Chronic Post-stroke Headache
Primary: Change in Modified Rankin Scale From Baseline to Follow-up 30 Days After Last Intervention — 0; 1 units on a scale — p=0.896
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=37 Cigarette Smoking Decision Study
Tobacco Smoking
Primary: Demand Intensity as Assessed by a Behavioral Economic Demand Curve — 4.709677419; 2.580645161 puff bouts
N/A N=14 Aim 1: App for Reducing Cravings to Smoke
Smoking
Primary: System Usability Scale (Aim 1) — 70.3 score on a scale
N/A N=60 Implementing CAPABLE in PSH
Accidental Fall · Frailty · Depression
Primary: Activities of Daily Living Limitations Score — 17.07; 14.47; 14.67; 13.17 Score on a scale
Phase 2 N=12 Gene Therapy for Painful Diabetic Neuropathy
Painful Diabetic Peripheral Neuropathy
Primary: Treatment-emergent Adverse Events for Participants Who Received Engensis 4 mg, 8 mg, or 16 mg — 3; 2; 2; 1 Participants
N/A N=12 Optimizing Protein Patterns for Skeletal Muscle Preservation and Sleep in the Medical Management of Parkinson Disease
Parkinson Disease
Primary: Change in Markers of Skeletal Muscle Metabolism GDF15
N/A N=236 LeukoSEQ: Whole Genome Sequencing as a First-Line Diagnostic Tool for Leukodystrophies
Leukodystrophy · White Matter Disease · 4H Syndrome
Primary: Changes in Diagnosis Status (Resulting From WGS) — 45 Participants
N/A N=32 Cardiometabolic Benefits of Potatoes Mediated Along the Gut-Vessel Axis in Adults With Metabolic Syndrome
Cardiovascular Diseases · Endotoxemia · Endothelial Dysfunction
Primary: Endotoxin — 21.2; 23.3 EU/mL
Phase 2 N=129 Trial to Evaluate the Efficacy and Safety of IVIEW-1201 in Acute Bacterial Conjunctivitis
Acute Bacterial Conjunctivitis
Primary: Clinical Cure Rate — 37; 31; 27; 33 Participants — p=0.0137
N/A N=268 Repeated-dose Behavioral Intervention to Reduce Opioid Overdose
Opioid-Related Disorders · Drug Overdose
Primary: Number of Overdose Events — 0; 0 overdoses
Phase 4 N=181 Cannabis and Tobacco Co-use Study
Tobacco Use Disorder
Primary: Number of Participants With Biologically Verified 7-day Point Prevalence Tobacco Abstinence at the End of Treatment (Week 12) — 30; 40; 36; 42 Participants
Phase 2 N=41 A Study of TAK-079 in Adults With Persistent/Chronic Primary Immune Thrombocytopenia
Primary Immune Thrombocytopenia
Primary: Percentage of Participants With at Least One Grade 3 or Higher Treatment Emergent Adverse Event (TEAE), Treatment Emergent Serious Adverse Event (SAE), and TEAEs Leading…
Phase 2 N=256 Platform Trial of Novel Regimens Versus Standard of Care (SoC) in Participants With Non-small Cell Lung Cancer (NSCLC)
Neoplasms
Primary: Number of Participants Randomized Across Sub-studies — 105; 8; 62 Participants
Phase 4 N=60 PEMF and PEC Blocks in Mastectomy Reconstruction Patients
Breast Cancer Female
Primary: Score on Visual Analog Scale (VAS) - 1 Hour Post-intervention — 6.64; 6.67; 4.62; 6.93 score on a scale
Phase 1 N=37 Study to Evaluate the Safety and Tolerability of PRO-231 Versus VIGAMOXI® on the Ocular Surface of Healthy Subjects
Ophthalmological Agent Toxicity · Bacterial Conjunctivitis
Primary: Incidence of Unexpected Adverse Events Related to the Interventions — 1; 4 number of related adverse events